TrialCancer communications (London, England)2025

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high-risk, HER2-negative breast cancer: An open-label, randomized controlled trial.

Yu Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.